Physician profile
David Grey
NPI 1215928759
$879.72
in general payments reported to CMS, 2019-2025
12 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.09 · 2021: $3.55 · 2023: $26.29 · 2024: $641 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545 · Travel and Lodging: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.96 |
| Travel and Lodging | $317.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $560.25 | 2024-2025 | Clareon, Centurion, Argos |
| Sun Pharmaceutical Industries INC. | $75.51 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $49.80 | 2024 | |
| Bausch & Lomb Americas INC. | $41.32 | 2024 | Xiidra, Miebo |
| Apellis Pharmaceuticals, INC. | $26.64 | 2025 | Syfovre |
| Abbvie INC. | $23.77 | 2024 | |
| Dompe US, INC. | $21.05 | 2024 | Oxervate |
| New World Medical,INC. | $20.60 | 2021-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Amgen INC. | $17.10 | 2024 | Tepezza |
| Thea Pharma INC. | $16.00 | 2024 | Iyuzeh |
| Allergan, INC. | $14.09 | 2019 | |
| Ocular Therapeutix, INC. | $13.59 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.